Global Irritable Bowel Syndrome Treatment Market Trends, Analysis, Growth, and Forecast: 2018 to 2027

MarketResearch.biz delivers in-depth insights on the global irritable bowel syndrome treatment market in its upcoming report titled, “Global Irritable Bowel Syndrome Treatment Market Trends, Analysis, Growth, and Forecast: 2018 to 2027”. The global irritable bowel syndrome treatment market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the global irritable bowel syndrome treatment market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report offers insightful and detailed information regarding the various key players operating in the global irritable bowel syndrome treatment market, their financials, supply chain trends, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global irritable bowel syndrome treatment market report has been segmented on the basis of drug type, medical condition, distribution channel, and region.

Request Covid - 19 Impact

Irritable bowel syndrome (IBS) is a gastrointestinal disorder that affects large intestine, symptom includes abdominal pain, altered bowel habits, increased gas, bloating (distention), cramping, and food intolerance. Moreover, these symptoms occur over long period for time. IBS is classified in three different types, IBS with constipation, IBS with diarrhea and IBS with alternating constipation & diarrhea. IBS affects more in women than in men. Currently there is no cure yet for IBS but the treatment includes change in diet, proper medication, and counseling and stress relief.

Increasing in levels of stress and adoption of sedentary lifestyle is expected to increase the prevalence gastrointestinal disorder disease is a major factor contributing for the growth of the global irritable bowel syndrome treatment market. In addition, company developing products with symptom specific indications and subsequent launches is another factors contributing for the growth of the global irritable bowel syndrome treatment market. Furthermore, increase in prevalence of irritable bowel syndrome in female is anticipated to further drive the growth of global irritable bowel treatment market over the forecast period.

A major factor restraining growth of the global irritable bowel syndrome treatment market is unsatisfactory effectiveness of the drugs which are commercialized.

However, company focusing on developing innovative and well-defined diagnosis for IBS, creating new opportunities for major players in the global irritable bowel treatment market over the forecast period.

North America market dominates the global irritable bowel syndrome treatment market in terms of revenue contribution as compared to that of markets in other regions. in the region. Europe accounts for second-largest revenue share contribution to the global irritable bowel syndrome treatment market, followed by markets in Latin America, Asia Pacific, and Middle East & Africa respectively. The market in Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years, owing to increasing investment by key market players in emerging market and increase in prevalence of gastrointestinal disorder.

Market Segmentation

Global irritable bowel syndrome treatment market segmentation, by drug type:

• Lubiprostone
• Linaclotide
• Eluxadoline
• Rifaximin
• Ramosetron Hydrochloride
• Others

 Global irritable bowel syndrome treatment market segmentation, by condition:

• IBS-Constipation
• IBS-Diarrhea

Global irritable bowel syndrome treatment market segmentation, by distribution channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

 Global irritable bowel syndrome treatment market segmentation, by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Abbott Laboratories
• Synergy Pharmaceuticals, Inc.
• Sucampo Pharmaceuticals, Inc.
• Valeant Pharmaceuticals International, Inc.
• Ardelyx, Inc.
• Astellas Pharma Inc.
• Novartis AG
• GlaxoSmithKline plc.
• Ironwood Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company